HCPLive Network

Pulmonary Congestion Predicts Death, Cardiac Events in Renal Disease

FRIDAY, March 1 (HealthDay News) -- Pulmonary congestion can predict risk of death and cardiac events in patients with end-stage renal disease undergoing dialysis, according to a study published online Feb. 28 in the Journal of the American Society of Nephrology.

Carmine Zoccali, MD, from the National Research Council-Institute of Biomedicine, in Pisa, Italy, and colleagues used a well validated ultrasound B-lines score (BL-US) to measure the extravascular lung water in 392 patients with end-stage renal disease receiving hemodialysis at one of multiple centers.

The researchers found that 45 percent of participants had moderate-to-severe lung congestion and 14 percent had very severe congestion. Seventy-one percent of patients with moderate-to-severe lung congestion were asymptomatic or presented slight symptoms of heart failure. Compared with those patients having mild or no congestion, patients with very severe congestion had a 4.2-fold increased risk of death and a 3.2-fold increased risk of cardiac events, even after adjustments for New York Heart Association class. There was also a significant 10 percent improvement in risk reclassification for cardiac events with the inclusion of the degree of pulmonary congestion into the model.

"In summary, lung ultrasound can detect asymptomatic pulmonary congestion in hemodialysis patients, and the resulting BL-US score is a strong, independent predictor of death and cardiac events in this population," the authors write.

Abstract
Full Text (subscription or payment may be required)

Copyright © 2013 HealthDay. All rights reserved.

Further Reading
Atherosclerotic internal carotid artery disease is a major contributor to ischemic stroke. Surgeons use a combination of carotid artery and brain imaging to determine if patients have symptomatic carotid stenosis. However, there remains widespread disagreement on the threshold, timing, and best technical approach to carotid revascularization in symptomatic patients.
The FDA has cleared a blood test that can screen patients, especially black women, for coronary heart disease.
The US Food and Drug Administration has announced the approval of a new combination treatment for hepatitis C virus.
More Reading